Taken together, these findings have largely dispelled our initial concerns regarding the potential for severe on-tumor and off-target side effects, such as cytokine storms, interstitial pneumonia, and hepatic impairment, resulting from combination therapy containing OHSV2-DSTEFAP5/CD3, because of the relatively low specificity of FAP and GPC3 target antigens, of course, suggesting that this novel strategy integrating different immune therapeutic drugs is worth further clinical development. This evidence concerns the gene FAP and neoplasm.